Thalidomide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Thalidomide
Thalidomide: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Thalidomide, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They are not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| multiple myeloma | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| plasma cell myeloma |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 6469L | Thalomid | Capsule 50 mg | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunomodulatory agent (thalidomide analogue class), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions. Neutropenia and agranulocytosis appear among the drug-disease contraindication edges. |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Full blood count with differential; neurological assessment for peripheral neuropathy; thromboembolism surveillance |
| Handling Protection | Please refer to the PI. Teratogenic risk applies, so pregnancy prevention requirements are critical. |
Safety Considerations
- Contraindication signals (knowledge graph, not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, epilepsy, neutropenia, agranulocytosis, peripheral nervous system disease, peripheral neuropathy, pulmonary embolism.
- Drug interactions: 100 interactions were identified; the first 20 reviewed are listed below.
- Major: hydrocortisone, triamcinolone, dexamethasone, betamethasone, prednisone.
- Moderate: famotidine, ranitidine, cimetidine, nizatidine, morphine, metronidazole, clarithromycin, levofloxacin, picosulfuric acid, dolasetron, palonosetron, ondansetron, metoclopramide, dronabinol, nabilone.
- Teratogenicity: thalidomide is a known teratogen that causes severe limb and other malformations, and this risk applies to any new use. Literature in the data also highlights irreversible axonal neuropathy and thromboembolism.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications, as label text was not available in the data compiled.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.